Le Lézard
Classified in: Health, Science and technology
Subject: ACC

DSM Announces Repurchase of Shares to Cover Share Based Compensation Plans and Stock Dividend


HEERLEN, the Netherlands, March 19, 2018 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials, today announces that it intends to repurchase 500,000 ordinary shares, starting on 19 March 2018, in order to cover commitments under share based compensation plans and 1,100,000 ordinary shares, starting on 14 May 2018, in order to cover commitments for stock dividend as part of the final dividend 2017. Based on the closing price of the DSM share on Euronext Amsterdam on 16 March 2018 this would be equivalent to approximately ?130 million.

     (Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )

DSM has signed a Discretionary Management Agreement with the bank that will execute the repurchase. The repurchase price will be based on the daily VWAP (Volume Weighted Average Price). Volumes to be repurchased will be on average 5% of the daily trading volume on the open market, within a bandwidth of 2-8% per day. The total share repurchase program is anticipated to continue into Q2 2018. The total number of shares to be repurchased under this program represents approximately 0.9% of ordinary shares issued.

In accordance with financial market regulations, DSM will inform the market about the progress made in the execution of this program through weekly press releases.

DSM - Bright Science. Brighter Living.tm 

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

For more information:
DSM Media Relations
Lieke de Jong
tel. +31(0)45-578-2421        
e-mail [email protected]

DSM Investor Relations
Dave Huizing
tel. +31(0)45-578-2864
e-mail [email protected]  

 

PDF - https://mma.prnewswire.com/media/655658/DSM_announces_repurchase_of_shares.pdf  

PRN NLD


These press releases may also interest you

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...



News published on and distributed by: